Case 3: PARP Inhibition in Recurrent Ovarian Cancer

Ovarian Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the C...Подробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

Recurrent Ovarian Cancer (2022)Подробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

Latest updates in low grade serous ovarian cancer treatment and researchПодробнее

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian CancerПодробнее

Case 3: Second-Line Therapy for Recurrent Ovarian CancerПодробнее

Case 3: The OCEANS and GOG-0213 Trials for Ovarian CancerПодробнее

Case 3: Maintenance Therapy for Recurrent Ovarian CancerПодробнее

PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry GeneticsПодробнее

Case 4: Recurrent Ovarian Cancer, Platinum-Resistant, BRCA WTПодробнее

Case 3: Molecular Testing in Recurrent Ovarian CancerПодробнее

Immunotherapy: The New Frontier of Cancer TherapyПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее